OR WAIT 15 SECS
The new company is the product of a merger with Formex.
BioDuro announced its official launch as a new company during the Biotechnology Innovation Organization (BIO) meeting in June 2016, focusing on its new identity as a full-service preclinical research and clinical development service provider. Prior to a recent merger with Formex, BioDuro focused mostly on early clinical development.
As a result of the merger, BioDuro adds expertise in formulation, development, and manufacture of drug product. It will offer bioavailability enhancement services for poorly soluble compounds and scale-up services for the preclinical and clinical manufacture of drug products.
Customers will also now have access to an additional 44,000 square feet of cGMP manufacturing space in San Diego. BioDuro has an existing 100,000-square-foot facility in Beijing, which serves as a biosimilar services hub focused on formulation and bioequivalence studies, as well as a center for synthetic chemistry; and a 92,000-square-foot facility in Shanghai dedicated to the company’s drug screening, bioanalysis, pharmacokinetic and pharmacodynamic studies, biomarker identification, and traditional research activities.